MLi-2, LRRK2 inhibitor (DMSO solution)
Be the first to review this product! Submit a review
|
(0 Publication)
MW 379.5 Da, Purity >98%. Potent and selective LRRK2 inhibitor. Inhibits LRRK2 in cell-free (IC50 = 0.76 nM), cell-based (IC50 = 1.4 nM) and radioligand-binding (IC50 = 3.4 nM) assays. Greater than 295-fold selective against a panel of receptors, channels and over 300 kinases. Oral dosing results in reduced Ser935 phosphorylation of LRRK2 in animal models.
View Alternative Names
AURA17, Dardarin, LRRK2_HUMAN, Leucine rich repeat kinase 2, Leucine-rich repeat serine/threonine-protein kinase 2, PARK 8, RIPK7, ROCO 2, augmented in rheumatoid arthritis 17, leucine rich repeat serine threonine protein kinase 2
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com